

Real-World HER2-Positive Early Breast Cancer Optimizing Curative Intent Therapy

WEDNESDAY, 15 MAY 2024 | 11:30–12:30 CEST

HUB27 BERLIN, MESSEDAMM 22
BERLIN, GERMANY | ROOM: FRANKFURT HALL

HYBRID 

CHAIR



Volkmar Müller, MD, PhD
Professor of Obstetrics and Gynecology
Head, Department of Gynecology
University Medical Center
Hamburg-Eppendorf
Hamburg, Germany

PANELISTS



**Lesley Fallowfield, DBE, BSc,
DPhil, FMedSci**
Professor of Psycho-Oncology
Sussex Health Outcomes Research
and Education in Cancer (SHORE-C)
Brighton and Sussex Medical School
University of Sussex
Brighton, United Kingdom



Qiang Liu, MD, PhD
Head of the Department of Breast Surgery
Sun Yat-Sen Memorial Hospital
Sun Yat-Sen University
Guangzhou, China

AGENDA

11:30

Welcome and Introduction
Volkmar Müller, MD, PhD

11:35

**Optimizing HER2-Positive Early Breast Cancer
Management: Where Are We Today?**
Volkmar Müller, MD, PhD

11:50

**Living With HER2: Understanding the Road
to Survivorship**
Lesley Fallowfield, DBE, BSc, DPhil, FMedSci

12:00

**Addressing Disparities Between Clinical
Trials and Clinical Practice: From Phase 3
to Real-World Settings**
Qiang Liu, MD, PhD

12:10

**Navigating Critical Decision Points in Care Pathways:
Exploring Best Practices Across Borders**
All Faculty

12:25

Q&A Session & Concluding Remarks
Volkmar Müller, MD, PhD

ACCREDITATION STATEMENT

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

WebMD Global

